Hepatocyte nuclear factor 1 beta (HNF1B) is transcription factor which plays a crucial role in the regulation of the development of several organs, but also seems to be implicated in the development of certain tumours, especially the subset of clear cell carcinomas of the ovary and kidney. Depending on the type of the tumour, HNF1B may act as either a tumour suppressor or an oncogene, although the exact mechanism by which HNF1B participates in the process of cancerogenesis is unknown. Using immunohistochemical approach and methylation and mutation analysis, we have investigated the expression, epigenetic, and genetic changes of HNF1B on 40 cases of colorectal adenomas and 105 cases of colorectal carcinomas. The expression of HNF1B was correlated with the benign or malignant behaviour of the lesion, given that carcinomas showed significantly lower levels of expression compared to adenomas. In carcinomas, lower levels of HNF1B expression were associated with recurrence and shortened disease-free survival. The mutation analysis revealed three somatic mutations (two frameshift and one nonsense) in the carcinoma sample set. Promoter methylation was detected in three carcinomas. These results suggest that in colorectal cancer, HNF1B may play a part in the pathogenesis and act in a tumour suppressive fashion.

1st Department of Surgery Department of Abdominal Thoracic Surgery and Traumatology 1st Faculty of Medicine Charles University and General University Hospital 12808 Prague Czech Republic

1st Faculty of Medicine Charles University and General University Hospital Prague 12800 Prague Czech Republic

Institute of Pathology 1st Faculty of Medicine Charles University and General University Hospital Prague Studnickova 2 12800 Prague 2 Czech Republic

Zobrazit více v PubMed

Liu Y, Kanyomse Q, Xie Y (2019) Tumor-suppressive activity of Hnf1beta in Wilms’ tumor. Biosci Biotechnol Biochem 83(11):2008–2015. https://doi.org/10.1080/09168451.2019.1611409 PubMed DOI

Yu DD, Guo SW, Jing YY, Dong YL, Wei LX (2015) A review on hepatocyte nuclear factor-1beta and tumor. Cell Biosci 5:58. https://doi.org/10.1186/s13578-015-0049-3 PubMed DOI PMC

Carithers LJ, Ardlie K, Barcus M, Branton PA, Britton A, Buia SA, Compton CC, DS DL, Peter-Demchok J, Gelfand ET, Guan P, Korzeniewski GE, Lockhart NC, Rabiner CA, Rao AK, Robinson KL, Roche NV, Sawyer SJ, Segre AV, Shive CE, Smith AM, Sobin LH, Undale AH, Valentino KM, Vaught J, Young TR, Moore HM, Consortium GT (2015) A novel approach to high-quality postmortem tissue procurement: the GTEx project. Biopreserv Biobank 13(5):311–319. https://doi.org/10.1089/bio.2015.0032 PubMed DOI PMC

Pontoglio M (2000) Hepatocyte nuclear factor 1, a transcription factor at the crossroads of glucose homeostasis. J Am Soc Nephrol 11(Suppl 16):S140–S143 PubMed

Suzuki E, Kajita S, Takahashi H, Matsumoto T, Tsuruta T, Saegusa M (2015) Transcriptional upregulation of HNF-1beta by NF-kappaB in ovarian clear cell carcinoma modulates susceptibility to apoptosis through alteration in bcl-2 expression. Lab Investig 95(8):962–972. https://doi.org/10.1038/labinvest.2015.73 PubMed DOI

Tsuchiya A, Sakamoto M, Yasuda J, Chuma M, Ohta T, Ohki M, Yasugi T, Taketani Y, Hirohashi S (2003) Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am J Pathol 163(6):2503–2512 DOI

Adalat S, Woolf AS, Johnstone KA, Wirsing A, Harries LW, Long DA, Hennekam RC, Ledermann SE, Rees L, van't Hoff W, Marks SD, Trompeter RS, Tullus K, Winyard PJ, Cansick J, Mushtaq I, Dhillon HK, Bingham C, Edghill EL, Shroff R, Stanescu H, Ryffel GU, Ellard S, Bockenhauer D (2009) HNF1B mutations associate with hypomagnesemia and renal magnesium wasting. J Am Soc Nephrol 20(5):1123–1131. https://doi.org/10.1681/ASN.2008060633 PubMed DOI PMC

Anik A, Catli G, Abaci A, Bober E (2015) Maturity-onset diabetes of the young (MODY): an update. J Pediatr Endocrinol Metab 28(3–4):251–263. https://doi.org/10.1515/jpem-2014-0384 PubMed DOI

Debiais-Delpech C, Godet J, Pedretti N, Bernard FX, Irani J, Cathelineau X, Cussenot O, Fromont G (2014) Expression patterns of candidate susceptibility genes HNF1beta and CtBP2 in prostate cancer: association with tumor progression. Urol Oncol 32(4):426–432. https://doi.org/10.1016/j.urolonc.2013.09.006 PubMed DOI

Elliott KS, Zeggini E, McCarthy MI, Gudmundsson J, Sulem P, Stacey SN, Thorlacius S, Amundadottir L, Gronberg H, Xu J, Gaborieau V, Eeles RA, Neal DE, Donovan JL, Hamdy FC, Muir K, Hwang SJ, Spitz MR, Zanke B, Carvajal-Carmona L, Brown KM, Australian Melanoma Family Study I, Hayward NK, Macgregor S, Tomlinson IP, Lemire M, Amos CI, Murabito JM, Isaacs WB, Easton DF, Brennan P, PanScan C, Barkardottir RB, Gudbjartsson DF, Rafnar T, Hunter DJ, Chanock SJ, Stefansson K, Ioannidis JP (2010) Evaluation of association of HNF1B variants with diverse cancers: collaborative analysis of data from 19 genome-wide association studies. PLoS One 5(5):e10858. https://doi.org/10.1371/journal.pone.0010858 PubMed DOI PMC

Glinsky GV, Glinskii AB, Stephenson AJ, Hoffman RM, Gerald WL (2004) Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest 113(6):913–923. https://doi.org/10.1172/JCI20032 PubMed DOI PMC

Janky R, Binda MM, Allemeersch J, Van den Broeck A, Govaere O, Swinnen JV, Roskams T, Aerts S, Topal B (2016) Prognostic relevance of molecular subtypes and master regulators in pancreatic ductal adenocarcinoma. BMC Cancer 16:632. https://doi.org/10.1186/s12885-016-2540-6 PubMed DOI PMC

Kondratyeva LG, Chernov IP, Zinovyeva MV, Kopantzev EP, Sverdlov ED (2017) Expression of master regulatory genes of embryonic development in pancreatic tumors. Dokl Biochem Biophys 475(1):250–252. https://doi.org/10.1134/S1607672917040020 PubMed DOI

Spurdle AB, Thompson DJ, Ahmed S, Ferguson K, Healey CS, O'Mara T, Walker LC, Montgomery SB, Dermitzakis ET, Australian National Endometrial Cancer Study G, Fahey P, Montgomery GW, Webb PM, Fasching PA, Beckmann MW, Ekici AB, Hein A, Lambrechts D, Coenegrachts L, Vergote I, Amant F, Salvesen HB, Trovik J, Njolstad TS, Helland H, Scott RJ, Ashton K, Proietto T, Otton G, National Study of Endometrial Cancer Genetics G, Tomlinson I, Gorman M, Howarth K, Hodgson S, Garcia-Closas M, Wentzensen N, Yang H, Chanock S, Hall P, Czene K, Liu J, Li J, Shu XO, Zheng W, Long J, Xiang YB, Shah M, Morrison J, Michailidou K, Pharoah PD, Dunning AM, Easton DF (2011) Genome-wide association study identifies a common variant associated with risk of endometrial cancer. Nat Genet 43(5):451–454. https://doi.org/10.1038/ng.812 PubMed DOI PMC

Yamamoto S, Tsuda H, Aida S, Shimazaki H, Tamai S, Matsubara O (2007) Immunohistochemical detection of hepatocyte nuclear factor 1beta in ovarian and endometrial clear-cell adenocarcinomas and nonneoplastic endometrium. Hum Pathol 38(7):1074–1080. https://doi.org/10.1016/j.humpath.2006.12.018 PubMed DOI

Rebouissou S, Vasiliu V, Thomas C, Bellanne-Chantelot C, Bui H, Chretien Y, Timsit J, Rosty C, Laurent-Puig P, Chauveau D, Zucman-Rossi J (2005) Germline hepatocyte nuclear factor 1alpha and 1beta mutations in renal cell carcinomas. Hum Mol Genet 14(5):603–614. https://doi.org/10.1093/hmg/ddi057 PubMed DOI

Painter JN, O'Mara TA, Batra J, Cheng T, Lose FA, Dennis J, Michailidou K, Tyrer JP, Ahmed S, Ferguson K, Healey CS, Kaufmann S, Hillman KM, Walpole C, Moya L, Pollock P, Jones A, Howarth K, Martin L, Gorman M, Hodgson S, National Study of Endometrial Cancer Genetics G, Consortium C, De Polanco MM, Sans M, Carracedo A, Castellvi-Bel S, Rojas-Martinez A, Santos E, Teixeira MR, Carvajal-Carmona L, Shu XO, Long J, Zheng W, Xiang YB, Australian National Endometrial Cancer Study G, Montgomery GW, Webb PM, Scott RJ, McEvoy M, Attia J, Holliday E, Martin NG, Nyholt DR, Henders AK, Fasching PA, Hein A, Beckmann MW, Renner SP, Dork T, Hillemanns P, Durst M, Runnebaum I, Lambrechts D, Coenegrachts L, Schrauwen S, Amant F, Winterhoff B, Dowdy SC, Goode EL, Teoman A, Salvesen HB, Trovik J, Njolstad TS, Werner HM, Ashton K, Proietto T, Otton G, Tzortzatos G, Mints M, Tham E, Rendocas HP, Czene K, Liu J, Li J, Hopper JL, Southey MC, Australian Ovarian Cancer S, Ekici AB, Ruebner M, Johnson N, Peto J, Burwinkel B, Marme F, Brenner H, Dieffenbach AK, Meindl A, Brauch H, Network G, Lindblom A, Depreeuw J, Moisse M, Chang-Claude J, Rudolph A, Couch FJ, Olson JE, Giles GG, Bruinsma F, Cunningham JM, Fridley BL, Borresen-Dale AL, Kristensen VN, Cox A, Swerdlow AJ, Orr N, Bolla MK, Wang Q, Weber RP, Chen Z, Shah M, French JD, Pharoah PD, Dunning AM, Tomlinson I, Easton DF, Edwards SL, Thompson DJ, Spurdle AB (2015) Fine-mapping of the HNF1B multicancer locus identifies candidate variants that mediate endometrial cancer risk. Hum Mol Genet 24(5):1478–1492. https://doi.org/10.1093/hmg/ddu552 PubMed DOI

Setiawan VW, Haessler J, Schumacher F, Cote ML, Deelman E, Fesinmeyer MD, Henderson BE, Jackson RD, Vockler JS, Wilkens LR, Yasmeen S, Haiman CA, Peters U, Le Marchand L, Kooperberg C (2012) HNF1B and endometrial cancer risk: results from the PAGE study. PLoS One 7(1):e30390. https://doi.org/10.1371/journal.pone.0030390 PubMed DOI PMC

Berndt SI, Sampson J, Yeager M, Jacobs KB, Wang Z, Hutchinson A, Chung C, Orr N, Wacholder S, Chatterjee N, Yu K, Kraft P, Feigelson HS, Thun MJ, Diver WR, Albanes D, Virtamo J, Weinstein S, Schumacher FR, Cancel-Tassin G, Cussenot O, Valeri A, Andriole GL, Crawford ED, Haiman C, Henderson B, Kolonel L, Le Marchand L, Siddiq A, Riboli E, Travis RC, Kaaks R, Isaacs W, Isaacs S, Wiley KE, Gronberg H, Wiklund F, Stattin P, Xu J, Zheng SL, Sun J, Vatten LJ, Hveem K, Njolstad I, Gerhard DS, Tucker M, Hayes RB, Hoover RN, Fraumeni JF Jr, Hunter DJ, Thomas G, Chanock SJ (2011) Large-scale fine mapping of the HNF1B locus and prostate cancer risk. Hum Mol Genet 20(16):3322–3329. https://doi.org/10.1093/hmg/ddr213 PubMed DOI PMC

Hindorff LA, Gillanders EM, Manolio TA (2011) Genetic architecture of cancer and other complex diseases: lessons learned and future directions. Carcinogenesis 32(7):945–954. https://doi.org/10.1093/carcin/bgr056 PubMed DOI PMC

Ross-Adams H, Ball S, Lawrenson K, Halim S, Russell R, Wells C, Strand SH, Orntoft TF, Larson M, Armasu S, Massie CE, Asim M, Mortensen MM, Borre M, Woodfine K, Warren AY, Lamb AD, Kay J, Whitaker H, Ramos-Montoya A, Murrell A, Sorensen KD, Fridley BL, Goode EL, Gayther SA, Masters J, Neal DE, Mills IG (2016) HNF1B variants associate with promoter methylation and regulate gene networks activated in prostate and ovarian cancer. Oncotarget 7(46):74734–74746. https://doi.org/10.18632/oncotarget.12543 PubMed DOI PMC

Matsui A, Fujimoto J, Ishikawa K, Ito E, Goshima N, Watanabe S, Semba K (2016) Hepatocyte nuclear factor 1 beta induces transformation and epithelial-to-mesenchymal transition. FEBS Lett 590(8):1211–1221. https://doi.org/10.1002/1873-3468.12147 PubMed DOI

Bosman FT, World Health Organization., International Agency for Research on Cancer (2010) WHO classification of tumours of the digestive system. World Health Organization classification of tumours, vol 3, 4th edn. International Agency for Research on Cancer, Lyon

Specht E, Kaemmerer D, Sanger J, Wirtz RM, Schulz S, Lupp A (2015) Comparison of immunoreactive score, HER2/neu score and H score for the immunohistochemical evaluation of somatostatin receptors in bronchopulmonary neuroendocrine neoplasms. Histopathology 67(3):368–377. https://doi.org/10.1111/his.12662 PubMed DOI

Gregova M, Hojny J, Nemejcova K, Bartu M, Mara M, Boudova B, Laco J, Krbal L, Ticha I, Dundr P (2019) Leiomyoma with bizarre nuclei: a study of 108 cases focusing on clinicopathological features, morphology, and fumarate hydratase alterations. Pathol Oncol Res. https://doi.org/10.1007/s12253-019-00739-5

Ticha I, Hojny J, Michalkova R, Kodet O, Krkavcova E, Hajkova N, Nemejcova K, Bartu M, Jaksa R, Dura M, Kanwal M, Martinikova AS, Macurek L, Zemankova P, Kleibl Z, Dundr P (2019) A comprehensive evaluation of pathogenic mutations in primary cutaneous melanomas, including the identification of novel loss-of-function variants. Sci Rep 9(1):17050. https://doi.org/10.1038/s41598-019-53636-x PubMed DOI PMC

Ticha I, Hojny J, Michalkova R, Kodet O, Krkavcova E, Hajkova N, Nemejcova K, Bartu M, Jaksa R, Dura M, Kanwal M, Martinikova AS, L. Macurek, Zemankova P, Kleibl Z, Dundr P (2019) A comprehensive evaluation of pathogenic mutations in primary cutaneous melanomas, including the identification of novel loss-of-function variants. Sci Rep Accepted for publication

Suraweera N, Duval A, Reperant M, Vaury C, Furlan D, Leroy K, Seruca R, Iacopetta B, Hamelin R (2002) Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. Gastroenterology 123(6):1804–1811. https://doi.org/10.1053/gast.2002.37070 PubMed DOI

Shen H, Fridley BL, Song H, Lawrenson K, Cunningham JM, Ramus SJ, Cicek MS, Tyrer J, Stram D, Larson MC, Kobel M, Consortium P, Ziogas A, Zheng W, Yang HP, Wu AH, Wozniak EL, Woo YL, Winterhoff B, Wik E, Whittemore AS, Wentzensen N, Weber RP, Vitonis AF, Vincent D, Vierkant RA, Vergote I, Van Den Berg D, Van Altena AM, Tworoger SS, Thompson PJ, Tessier DC, Terry KL, Teo SH, Templeman C, Stram DO, Southey MC, Sieh W, Siddiqui N, Shvetsov YB, Shu XO, Shridhar V, Wang-Gohrke S, Severi G, Schwaab I, Salvesen HB, Rzepecka IK, Runnebaum IB, Rossing MA, Rodriguez-Rodriguez L, Risch HA, Renner SP, Poole EM, Pike MC, Phelan CM, Pelttari LM, Pejovic T, Paul J, Orlow I, Omar SZ, Olson SH, Odunsi K, Nickels S, Nevanlinna H, Ness RB, Narod SA, Nakanishi T, Moysich KB, Monteiro AN, Moes-Sosnowska J, Modugno F, Menon U, McLaughlin JR, McGuire V, Matsuo K, Adenan NA, Massuger LF, Lurie G, Lundvall L, Lubinski J, Lissowska J, Levine DA, Leminen A, Lee AW, Le ND, Lambrechts S, Lambrechts D, Kupryjanczyk J, Krakstad C, Konecny GE, Kjaer SK, Kiemeney LA, Kelemen LE, Keeney GL, Karlan BY, Karevan R, Kalli KR, Kajiyama H, Ji BT, Jensen A, Jakubowska A, Iversen E, Hosono S, Hogdall CK, Hogdall E, Hoatlin M, Hillemanns P, Heitz F, Hein R, Harter P, Halle MK, Hall P, Gronwald J, Gore M, Goodman MT, Giles GG, Gentry-Maharaj A, Garcia-Closas M, Flanagan JM, Fasching PA, Ekici AB, Edwards R, Eccles D, Easton DF, Durst M, du Bois A, Dork T, Doherty JA, Despierre E, Dansonka-Mieszkowska A, Cybulski C, Cramer DW, Cook LS, Chen X, Charbonneau B, Chang-Claude J, Campbell I, Butzow R, Bunker CH, Brueggmann D, Brown R, Brooks-Wilson A, Brinton LA, Bogdanova N, Block MS, Benjamin E, Beesley J, Beckmann MW, Bandera EV, Baglietto L, Bacot F, Armasu SM, Antonenkova N, Anton-Culver H, Aben KK, Liang D, Wu X, Lu K, Hildebrandt MA, Australian Ovarian Cancer Study G, Australian Cancer S, Schildkraut JM, Sellers TA, Huntsman D, Berchuck A, Chenevix-Trench G, Gayther SA, Pharoah PD, Laird PW, Goode EL, Pearce CL (2013) Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nat Commun 4:1628. https://doi.org/10.1038/ncomms2629 PubMed DOI PMC

Wojdacz TK, Dobrovic A, Hansen LL (2008) Methylation-sensitive high-resolution melting. Nat Protoc 3(12):1903–1908. https://doi.org/10.1038/nprot.2008.191 PubMed DOI

Lau HH, Ng NHJ, Loo LSW, Jasmen JB, Teo AKK (2018) The molecular functions of hepatocyte nuclear factors - in and beyond the liver. J Hepatol 68(5):1033–1048. https://doi.org/10.1016/j.jhep.2017.11.026 PubMed DOI

Rezanejad H, Ouziel-Yahalom L, Keyzer CA, Sullivan BA, Hollister-Lock J, Li WC, Guo L, Deng S, Lei J, Markmann J, Bonner-Weir S (2018) Heterogeneity of SOX9 and HNF1beta in pancreatic ducts is dynamic. Stem Cell Reports 10(3):725–738. https://doi.org/10.1016/j.stemcr.2018.01.028 PubMed DOI PMC

Senkel S, Lucas B, Klein-Hitpass L, Ryffel GU (2005) Identification of target genes of the transcription factor HNF1beta and HNF1alpha in a human embryonic kidney cell line. Biochim Biophys Acta 1731(3):179–190. https://doi.org/10.1016/j.bbaexp.2005.10.003 PubMed DOI

Kobel M, Kalloger SE, Carrick J, Huntsman D, Asad H, Oliva E, Ewanowich CA, Soslow RA, Gilks CB (2009) A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary. Am J Surg Pathol 33(1):14–21. https://doi.org/10.1097/PAS.0b013e3181788546 PubMed DOI

Lebrun G, Vasiliu V, Bellanne-Chantelot C, Bensman A, Ulinski T, Chretien Y, Grunfeld JP (2005) Cystic kidney disease, chromophobe renal cell carcinoma and TCF2 (HNF1 beta) mutations. Nat Clin Pract Nephrol 1(2):115–119. https://doi.org/10.1038/ncpneph0054 PubMed DOI

Nemejcova K, Cibula D, Dundr P (2015) Expression of HNF-1beta in cervical carcinomas: an immunohistochemical study of 155 cases. Diagn Pathol 10:8. https://doi.org/10.1186/s13000-015-0245-9 PubMed DOI PMC

Bartu M, Dundr P, Nemejcova K, Ticha I, Hojny H, Hajkova N (2018) The role of HNF1B in tumorigenesis of solid Tumours: a review of current knowledge. Folia Biol (Praha) 64(3):71–83

Harries LW, Perry JR, McCullagh P, Crundwell M (2010) Alterations in LMTK2, MSMB and HNF1B gene expression are associated with the development of prostate cancer. BMC Cancer 10:315. https://doi.org/10.1186/1471-2407-10-315 PubMed DOI PMC

Kim HJ, Bae JS, Lee J, Chang IH, Kim KD, Shin HD, Han JH, Lee SY, Kim W, Myung SC (2011) HNF1B polymorphism associated with development of prostate cancer in Korean patients. Urology 78(4):969 e961–969 e966. https://doi.org/10.1016/j.urology.2011.06.045 DOI

Mandato VD, Farnetti E, Torricelli F, Abrate M, Casali B, Ciarlini G, Pirillo D, Gelli MC, Nicoli D, Grassi M, LAS GB, Palomba S (2015) HNF1B polymorphism influences the prognosis of endometrial cancer patients: a cohort study. BMC Cancer 15:229. https://doi.org/10.1186/s12885-015-1246-5 PubMed DOI PMC

Kountourakis P, Souglakos J, Gouvas N, Androulakis N, Athanasiadis A, Boukovinas I, Christodoulou C, Chrysou E, Dervenis C, Emmanouilidis C, Georgiou P, Karachaliou N, Katopodi O, Makatsoris T, Papakostas P, Pentheroudakis G, Pilpilidis I, Sgouros J, Tekkis P, Triantopoulou C, Tzardi M, Vassiliou V, Vini L, Xynogalos S, Xynos E, Ziras N, Papamichael D (2016) Adjuvant chemotherapy for colon cancer: a consensus statement of the Hellenic and Cypriot Colorectal Cancer Study Group by the HeSMO. Ann Gastroenterol 29(1):18–23 PubMed PMC

Silva TD, Vidigal VM, Felipe AV, DEL JM, Neto RA, Saad SS, Forones NM (2013) DNA methylation as an epigenetic biomarker in colorectal cancer. Oncol Lett 6(6):1687–1692. https://doi.org/10.3892/ol.2013.1606 PubMed DOI PMC

Terasawa K, Toyota M, Sagae S, Ogi K, Suzuki H, Sonoda T, Akino K, Maruyama R, Nishikawa N, Imai K, Shinomura Y, Saito T, Tokino T (2006) Epigenetic inactivation of TCF2 in ovarian cancer and various cancer cell lines. Br J Cancer 94(6):914–921. https://doi.org/10.1038/sj.bjc.6602984 PubMed DOI PMC

Suaud L, Joseph B, Formstecher P, Laine B (1997) mRNA expression of HNF-4 isoforms and of HNF-1alpha/HNF-1beta variants and differentiation of human cell lines that mimic highly specialized phenotypes of intestinal epithelium. Biochem Biophys Res Commun 235(3):820–825. https://doi.org/10.1006/bbrc.1997.6888 PubMed DOI

Yang R, Kerschner JL, Harris A (2016) Hepatocyte nuclear factor 1 coordinates multiple processes in a model of intestinal epithelial cell function. Biochim Biophys Acta 1859(4):591–598. https://doi.org/10.1016/j.bbagrm.2016.02.005 PubMed DOI PMC

D'Angelo A, Bluteau O, Garcia-Gonzalez MA, Gresh L, Doyen A, Garbay S, Robine S, Pontoglio M (2010) Hepatocyte nuclear factor 1alpha and beta control terminal differentiation and cell fate commitment in the gut epithelium. Development 137(9):1573–1582. https://doi.org/10.1242/dev.044420 PubMed DOI

Amano Y, Mandai M, Yamaguchi K, Matsumura N, Kharma B, Baba T, Abiko K, Hamanishi J, Yoshioka Y, Konishi I (2015) Metabolic alterations caused by HNF1beta expression in ovarian clear cell carcinoma contribute to cell survival. Oncotarget 6(28):26002–26017. https://doi.org/10.18632/oncotarget.4692 PubMed DOI PMC

Rougemont AL, Tille JC (2018) Role of HNF1beta in the differential diagnosis of yolk sac tumor from other germ cell tumors. Hum Pathol 81:26–36. https://doi.org/10.1016/j.humpath.2018.04.025 PubMed DOI

Zheng J, Liu X, Xue Y, Gong W, Ma J, Xi Z, Que Z, Liu Y (2017) TTBK2 circular RNA promotes glioma malignancy by regulating miR-217/HNF1beta/Derlin-1 pathway. J Hematol Oncol 10(1):52. https://doi.org/10.1186/s13045-017-0422-2 PubMed DOI PMC

The cytokeratin 17 expression in primary ovarian tumors has diagnostic but not prognostic significance

Comprehensive quantitative analysis of alternative splicing variants reveals the HNF1B mRNA splicing pattern in various tumour and non-tumour tissues

A comprehensive analysis of the expression, epigenetic and genetic changes of HNF1B and ECI2 in 122 cases of high-grade serous ovarian carcinoma

Analysis of expression, epigenetic, and genetic changes of HNF1B in 130 kidney tumours

HNF1B, EZH2 and ECI2 in prostate carcinoma. Molecular, immunohistochemical and clinico-pathological study